Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience

Annals of Surgical Oncology

Volumn 22, Issue , 2015, Pages 1212-1220

  Nitsche, Ulrich ^a   Wenzel, Patrick ^a   Siveke, Jens T ^a   Braren, Rickmer ^a   Holzapfel, Konstantin ^a   Schlitter, Anna M ^b   Stöß, Christian ^a   Kong, Bo ^a   Esposito, Irene ^c   Erkan, Mert ^d   Michalski, Christoph W ^e   Friess, Helmut ^a   Kleeff, Jörg ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d KOÇ UNIVERSITY   (Turkey)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CLINICAL ARTICLE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LAPAROTOMY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; CANCER STAGING; CARCINOMA, PANCREATIC DUCTAL; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PANCREAS RESECTION; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, PANCREATIC DUCTAL; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84952872152     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-015-4851-2     Document Type: Article

References (34)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.
2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21.
3. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378(9791):607–20.
4. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073–81.
5. Seufferlein T, Porzner M, Becker T, et al. [S3-guideline exocrine pancreatic cancer]. Zeitschrift Gastroenterol. 2013;51(12):1395–440.
6. Tempero MA, Malafa MP, Behrman SW, et al. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Comp Cancer Network. 2014;12(8):1083–93.
7. Morganti AG, Massaccesi M, La Torre G, et al. A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann Surg Oncol. 2010;17(1):194–205.
8. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.
9. Faris JE, Blaszkowsky LS, McDermott S, et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist. 2013;18(5):543–8.
10. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4):e1000267.
11. Petrelli F, Coinu A, Borgonovo K, et al. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies. Pancreas. 2015;44(4):515–21.
12. Hosein PJ, Macintyre J, Kawamura C, et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012;12:199.
13. Boone BA, Steve J, Krasinskas AM, et al. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol. 2013;108(4):236–41.
14. Peddi PF, Lubner S, McWilliams R, et al. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. J Pancreas. 2012;13(5):497–501.
15. Christians KK, Tsai S, Mahmoud A, et al. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist. 2014;19(3):266–74.
16. Paniccia A, Edil BH, Schulick RD, et al. Neoadjuvant FOLFIRINOX application in borderline resectable pancreatic adenocarcinoma: a retrospective cohort study. Medicine. 2014;93(27):e198.
17. Moorcraft SY, Khan K, Peckitt C, et al. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: The Royal Marsden Experience. Clin Colorectal Cancer. 2014;13(4):232–8.
18. Valeri S, Borzomati D, Nappo G, Perrone G, Santini D, Coppola R. Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature. Pancreatology. 2014;14(5):425–30.
19. Blazer M, Wu C, Goldberg RM, et al. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol. 2014;22(4):1153–9.
20. Marthey L, Sa-Cunha A, Blanc JF, et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Ann Surg Oncol. 2015;22(1):295–301.
21. Gunturu KS, Yao X, Cong X, et al. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Med Oncol. 2013;30(1):361.
22. Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015;261(1):12–7.
23. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–55.
24. Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127(11):1335–9.
25. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.
26. Esposito I, Kleeff J, Bergmann F, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol. 2008;15(6):1651–60.
27. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Exokrines Pankreaskarzinom, Leitlinienreport 1.0, 2013, AWMF-Registernummer: 032/010OL. http://leitlinienprogramm-onkologie.de/Leitlinien.7.0.html. Accessed 1 July 2015.
28. Common Terminology Criteria for Adverse Events (CTCAE), Published: May 28, 2009 (Version 4.03: June 14, 2010). http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf.
29. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
30. Prenzel KL, Holscher AH, Vallbohmer D, et al. Lymph node size and metastatic infiltration in adenocarcinoma of the pancreatic head. Eur J Surg Oncol. 2010;36(10):993–6.
31. Zanini N, Masetti M, Jovine E. The definition of locally advanced pancreatic cancer. BrJ Cancer. 2010;102(8):1306–7.
32. Bockhorn M, Uzunoglu FG, Adham M, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014;155(6):977–88.
33. Saville DJ. Multiple comparison procedures: the practical solution. Am Stat. 1990;44(2):174–80.
34. Tempero MA, Arnoletti JP, Behrman SW, et al. Pancreatic adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Comp Cancer Network. 2012;10(6):703–13.